Non-alcoholic Fatty Liver Disease Clinical Trial
Official title:
The Impact of Autonomic Dysfunction on Liver-Related Symptoms in Non-Alcoholic Fatty Liver Disease and Their Relationship to Systemic Inflammation and Insulin Resistance
There is a significant association between autonomic dysfunction and symptoms experienced by NAFLD patients mediated by increased systemic inflammation and insulin resistance, resulting in deteriorating quality of life of affected patients; fatigue and other symptoms drive worsening autonomic dysfunction in these patients. We aim to describe the severity of autonomic dysfunction (AD) in non-alcoholic fatty liver disease (NAFLD) and the relationship of AD to symptoms experienced by NAFLD patients (such as fatigue, chronic pain, depression, sleep disturbance, and cognitive dysfunction), and to the quality of life of NAFLD patients. We also hope to examine the impact of systemic inflammation and insulin resistance as mediators of manifestations of AD and symptoms experienced by NAFLD patients.
Aim 1. Describe the severity of AD in NAFLD and the relationship of AD to symptoms
experienced by NAFLD patients (fatigue, chronic pain, depression, sleep disturbance, and
cognitive dysfunction) (Aim 1a) and to the quality of life of NAFLD patients (Aim 1b).
Primary screening for inclusion/exclusion criteria will be done at the VCUHS clinic.
Subjects meeting inclusion criteria will be approached about study participation during
their routine NAFLD clinic visit. Those who agree to participate in the study will return
for a study visit at the CCTR Clinical Research Services. All subjects will be asked to fast
and avoid caffeine for 12 hours prior to study visit. Demographic and clinical data will be
collected by study coordinators. After a focused exam, conducted by a hepatologist to
determine health status of the participants, the PI and a research nurse will interview
participants to assess their symptoms and AD (Aim 1). Blood (20 ml) samples will be
collected via venipuncture for serum and plasma inflammatory markers and IR (Aim 2).
Aim 2. Examine the impact of systemic inflammation (SI) and insulin resistance (IR) as
mediators of manifestations of AD and symptoms experienced by NAFLD patients. Increased
presence of adipocytes may produce high, chronic levels of cytokines such as IL-6 and TNF-α
resulting in higher levels of APRPs which contribute to overall inflammation as well as
cognitive decline and fatigue. Secondly, elevated levels of IL-6 and TNF-α lower levels of
CTRPs which exacerbate IR, AD, and muscle and cardiac problems reported in NAFLD. Through
the use of plasma analysis, levels of cytokines such as IL-6, TNF-α, and APRPs can be
performed in a high throughput BioPlex® assay (Bio-Rad Laboratories, Inc.: Hercules, CA). We
have extensive experience with these types of assays and have generated data using human
samples in numerous studies conducted through the Center of Excellence for Biobehavioral
Approaches to Symptom Management (CEBASM) at the School of Nursing. CTRP family members are
also expressed in the plasma and at detectible levels. We will perform ELISA analysis to
compare circulating levels of the various CTRPs using commercially available CTRP ELISA
kits/reagents. Insulin resistance (IR) will be assessed by HOMO-IR utilizing fasting glucose
and insulin.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |